Skip to content
DataLookout
Menu

NCT07526974

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 24 words
    • Start date changed from estimate of Oct 2026 to Nov 9, 2026
    • Study sites: 14 to 15
    • Study description shortened, about 1 word
  2. Notable Eligibility criteria expanded, about 26 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of participants achieving at least a 2-grade improvement on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.
Timeframe: From baseline to 4 weeks after final treatment

Secondary (2)

Percentage change from baseline in abdominal fat in the CBL-514 group versus the placebo group.
Percentage of participants with at least a 1-grade improvement on both Participant Reported Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.

Arms and interventions

CBL-514 injectionExperimental

Participants will receive CBL-514 administered up to 120 mL per treatment at a 4-weeks interval for up to 4 treatments.

Injectable 0.9% Sodium Chloride solutionPlacebo comparator

Participants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 4-week interval for up to 4 treatments.

Drugs: CBL-514 Injection, 0.9% Sodium Chloride

Sites

15 sites in 2 countries

United States 13, Canada 2